RnRMarketResearch.com adds ‘Schizophrenia Pipeline Review, H2 2015’ Market Research to its database, providing in-depth, high quality, transparent and market-driven, expert’s analysis.
This research provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.
The research enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Inquire before buying this research at: http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=459962 .
This research features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together. Drug profiles/records featured in the research undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope for this research:
· The report provides a snapshot of the global therapeutic landscape of Schizophrenia
· The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
· The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects
· The report summarizes all the dormant and discontinued pipeline projects
· A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
· Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
· A detailed assessment of monotherapy and combination therapy pipeline projects
· Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type
· Latest news and deals relating related to pipeline products
Complete research on H2 Pipeline Review of ‘Schizophrenia’ spread across 374 pages at http://www.rnrmarketresearch.com/schizophrenia-pipeline-review-h2-2015-market-report.html .
Reasons to buy this research:
· Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
· Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
· Develop strategic initiatives by understanding the focus areas of leading companies
· Identify and understand important and diverse types of therapeutics under development for Schizophrenia
· Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
· Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
· Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
· Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned: Acadia Pharmaceuticals Inc., Aequus Pharmaceuticals Inc., Aestus Therapeutics, Inc., AgeneBio Inc., Alkermes Plc, Amgen Inc., Angita B.V., ANP Technologies, Inc., Astellas Pharma Inc., Athersys, Inc., BCWorld Pharm Co. Ltd., BioCrea GmbH, Boehringer Ingelheim GmbH, Braeburn Pharmaceuticals, Inc., Catalyst Biosciences, Inc., Critical Pharmaceuticals Limited, Curemark, LLC, Delpor, Inc., Dong Wha Pharma Co., Ltd., Echo Pharmaceuticals B.V., Egis Gyogyszergyar Nyrt, Eli Lilly and Company, Evotec AG, F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., Galenea Corp., GeNeuro SA, Genovate Biotechnology Co., LTD., Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., GP Pharm, S.A., GW Pharmaceuticals Plc, H. Lundbeck A/S, Heptares Therapeutics Limited, Hisamitsu Pharmaceutical Co., Inc., Indivior Plc, INSYS Therapeutics, Inc., Integrative Research Laboratories Sweden AB, IntelGenx Corp., Intra-Cellular Therapies, Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiangsu Nhwa Pharmaceutical Corporation Ltd., Johnson & Johnson, Karuna Pharmaceuticals Inc., KemPharm, Inc., Laboratorios Farmaceuticos Rovi, S.A., Lead Discovery Center GmbH, Lohocla Research Corporation, Luye Pharma Group Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Neuralstem, Inc., Neurocrine Biosciences, Inc., NeurOp, Inc, Newron Pharmaceuticals S.p.A., Omeros Corporation, Otsuka Holdings Co., Ltd., Peptron, Inc., Pfizer Inc., Promentis Pharmaceuticals, Inc., PsychoGenics, Inc., Reviva Pharmaceuticals Inc., Richter Gedeon Nyrt., Saniona AB, SK Biopharmaceuticals Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sunovion Pharmaceuticals Inc., Suven Life Sciences Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Takeda Pharmaceutical Company Limited, Tetra Discovery Partners LLC, Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., XTL Biopharmaceuticals Ltd., Zogenix, Inc., Zysis Limited